Gene therapy strategies and prospects for neurofibromatosis type 1.
10.7507/1002-1892.202309071
- Author:
Tingting ZHENG
1
;
Beiyao ZHU
1
;
Zhichao WANG
1
;
Qingfeng LI
1
Author Information
1. Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, P. R. China.
- Publication Type:Journal Article
- Keywords:
NF1 gene;
Neurofibromatosis type 1;
gene editing;
transgenic therapy
- MeSH:
Humans;
Neurofibromatosis 1/pathology*;
Neurofibromin 1/metabolism*;
GTPase-Activating Proteins;
Mutation;
Genetic Predisposition to Disease;
Genetic Therapy
- From:
Chinese Journal of Reparative and Reconstructive Surgery
2024;38(1):1-8
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To summarize the gene therapy strategies for neurofibromatosis type 1 (NF1) and related research progress.
METHODS:The recent literature on gene therapy for NF1 at home and abroad was reviewed. The structure and function of the NF1 gene and its mutations were analyzed, and the current status as well as future prospects of the transgenic therapy and gene editing strategies were summarized.
RESULTS:NF1 is an autosomal dominantly inherited tumor predisposition syndrome caused by mutations in the NF1 tumor suppressor gene, which impair the function of the neurofibromin and lead to the disease. It has complex clinical manifestations and is not yet curable. Gene therapy strategies for NF1 are still in the research and development stage. Existing studies on the transgenic therapy for NF1 have mainly focused on the construction and expression of the GTPase-activating protein-related domain in cells that lack of functional neurofibromin, confirming the feasibility of the transgenic therapy for NF1. Future research may focus on split adeno-associated virus (AAV) gene delivery, oversized AAV gene delivery, and the development of new vectors for targeted delivery of full-length NF1 cDNA. In addition, the gene editing tools of the new generation have great potential to treat monogenic genetic diseases such as NF1, but need to be further validated in terms of efficiency and safety.
CONCLUSION:Gene therapy, including both the transgenic therapy and gene editing, is expected to become an important new therapeutic approach for NF1 patients.
